5 completed, 1 terminated. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
Follow AFM13: new trials by email Literature Review of AFM13 trials Research Report on AFM13
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL AFM13, AB-101, Cyclophosphamide - Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Terminated | Affimed GmbH | 25 | 2023-10-10 | 2025-08-20 |
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2020-07-18 | 2026-09-30 |
| Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides AFM13 - Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides | Phase 2 | Completed | Affimed GmbH | 108 | 2019-11-13 | 2024-11-05 |
| AFM13 in Relapsed/Refractory Cutaneous Lymphomas AFM13 - Lymphoma, T-Cell, Cutaneous | Phase 1 / Phase 2 | Completed | Ahmed Sawas | 18 | 2017-07-17 | 2023-07-20 |
| Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma AFM13, Pembrolizumab - Hodgkin Lymphoma | Phase 1 | Completed | Affimed GmbH | 30 | 2016-05-01 | 2019-05-16 |
| GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma AFM13 - Hodgkin Lymphoma | Phase 2 | Completed | University of Cologne | 23 | 2015-05-01 | 2020-11-13 |
Hodgkin Disease (3) · Lymphoma, T-Cell (2) · Lymphoma, T-Cell, Peripheral (2) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Recurrence (1)
Affimed GmbH (3) · Ahmed Sawas (1) · M.D. Anderson Cancer Center (1) · University of Cologne (1)
United States (5) · Germany (2) · Spain (2) · Australia (1) · France (1) · Italy (1) · Poland (1) · Russia (1) · South Korea (1) · Turkey (Türkiye) (1)
Ahmed Sawas, MD (1) · Andreas Engert, Prof. (1) · Karenza Alexis, MD (1) · Steven Horwitz, MD (1) · Won Seog Kim, Dr (1) · Wunderle Lydia, MD (1) · Yago L Nieto (1)
PMID 32730586, PMID 35848865, PMID 40186077
2014 (1)